TickerGuard
Buy Day today: Poor (44) Weak market breadth · today: Core PCE (August) ≈
KYMR

Kymera Therapeutics Inc

Healthcare · Biotechnology

115.50$ -5.4% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Income Statement

Kymera Therapeutics Inc (KYMR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 65 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement KYMR
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
4.7 48 10 26 3.7 7.4 22 11 2.8 2.9 34 65 105
0.9 0.9 1.5 1.9 2.0 2.0 2.0 2.1 74 -76 2.0 – –
4.7 48 10 26 3.7 7.4 22 9.4 -71 79 34 65 107
48 53 49 59 60 72 80 78 74 84 98 119 376
14 14 14 17 15 16 16 18 17 17 20 21 76
62 67 68 77 76 88 97 94 21 177 119 141 457
-58 -19 -58 -51 -72 -81 -74 -85 -93 -98 -84 -76 -350
0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.3
-53 -14 -49 -42 -62 -71 -66 -77 -82 -87 -69 -61 -300
-0.9 5.0 0.0 – -2.0 – – – – – – – –
-53 -14 -49 -42 -62 -71 -66 -77 -82 -87 -69 -61 -300
-52 -13 -47 -40 -60 -69 -63 -74 -79 -85 -67 -61 -293

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?